Login Register Cart 0
Review Article

c-Jun N-末端激酶(JNK)抑制剂的研究进展

卷 28, 期 3, 2021

发表于: 10 February, 2020

页: [607 - 627] 页: 21

弟呕挨: 10.2174/0929867327666200210144114

价格: $65

摘要

c-Jun N-末端激酶(JNKs)是丝裂原活化蛋白激酶(MAPK)信号通路的成员，在许多疾病的发病机制中发挥关键作用，包括癌症、炎症、帕金森病、阿尔茨海默病、心血管疾病、肥胖和糖尿病。因此，JNKs是治疗药物新的优良靶点。在过去的十年中，人们发现了许多基于不同分子支架的JNK抑制剂。然而，只有少数药物进入了临床试验阶段。JNK抑制剂作为治疗药物发展的主要障碍是jnk亚型的选择性。本文综述了JNK抑制剂的最新进展，包括ATP竞争性和ATP非竞争性(别构)抑制剂、双齿结合抑制剂和双齿抑制剂，以及JNK抑制剂作为潜在治疗药物面临的挑战和未来的发展方向。

关键词: JNK，抑制剂，ATP结合位点，JNK亚型选择性，变构，双齿，丝裂原活化蛋白激酶(MAPK)

« Previous Next »
[1]
Zhou, Y.Y.; Li, Y.; Jiang, W.Q.; Zhou, L.F. MAPK/JNK signalling: a potential autophagy regulation pathway. Biosci. Rep., 2015, 35(3)e00199
[http://dx.doi.org/10.1042/BSR20140141] [PMID: 26182361]
[2]
Papa, S.; Choy, P.M.; Bubici, C. The ERK and JNK pathways in the regulation of metabolic reprogramming. Oncogene, 2019, 38(13), 2223-2240.
[http://dx.doi.org/10.1038/s41388-018-0582-8] [PMID: 30487597]
[3]
Lu, L.; Liu, Q.; Wang, P.; Wu, Y.; Liu, X.; Weng, C.; Fang, X.; Li, B.; Cao, X.; Mao, H.; Wang, L.; Guan, M.; Wang, W.; Liu, G. MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway. BMC Cancer, 2019, 19(1), 209.
[http://dx.doi.org/10.1186/s12885-019-5400-3] [PMID: 30849960]
[4]
Zhang, Q.; Luna-Vital, D.; de Mejia, G.E. Anthocyanins from colored maize ameliorated the inflammatory paracrine interplay between macrophages and adipocytes through regulation of NF-B and JNK-dependent MAPK pathways. J. Funct. Foods, 2019, 54, 175-186.
[http://dx.doi.org/10.1016/j.jff.2019.01.016]
[5]
Wolle, P.; Hardick, J.; Cronin, S.J.F.; Engel, J.; Baumann, M.; Lategahn, J.; Penninger, J.M.; Rauh, D. Targeting the MKK7-JNK (mitogen-activated protein kinase kinase 7-c-Jun N-terminal kinase) pathway with covalent inhibitors. J. Med. Chem., 2019, 62(5), 2843-2848.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00102] [PMID: 30768270]
[6]
Grynberg, K.; Ma, F.Y.; Nikolic-Paterson, D.J. The JNK signaling pathway in renal fibrosis. Front. Physiol., 2017, 8, 829.
[http://dx.doi.org/10.3389/fphys.2017.00829] [PMID: 29114233]
[7]
Bubici, C.; Papa, S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br. J. Pharmacol., 2014, 171(1), 24-37.
[http://dx.doi.org/10.1111/bph.12432] [PMID: 24117156]
[8]
Garnica, P.; Encío, I.; Plano, D.; Palop, J.A.; Sanmartín, C. Organoseleno cytostatic derivatives: autophagic cell death with AMPK and JNK activation. Eur. J. Med. Chem., 2019, 175, 234-246.
[http://dx.doi.org/10.1016/j.ejmech.2019.04.074] [PMID: 31082766]
[9]
Shakya, B.; Shahi, N.; Ahmad, F.; Yadav, P.N.; Pokharel, Y.R. 2-Pyridineformamide N(4)-ring incorporated thiosemicarbazones inhibit MCF-7 cells by inhibiting JNK pathway. Bioorg. Med. Chem. Lett., 2019, 29(13), 1677-1681.
[http://dx.doi.org/10.1016/j.bmcl.2019.04.031] [PMID: 31053506]
[10]
Solinas, G.; Becattini, B. JNK at the crossroad of obesity, insulin resistance, and cell stress response. Mol. Metab., 2016, 6(2), 174-184.
[http://dx.doi.org/10.1016/j.molmet.2016.12.001] [PMID: 28180059]
[11]
Grabiec, A.M.; Angiolilli, C.; Hartkamp, L.M.; van Baarsen, L.G.; Tak, P.P.; Reedquist, K.A. JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis. Ann. Rheum. Dis., 2015, 74(9), 1763-1771.
[http://dx.doi.org/10.1136/annrheumdis-2013-203610] [PMID: 24812285]
[12]
Yarza, R.; Vela, S.; Solas, M.; Ramirez, M.J. c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer’s disease. Front. Pharmacol., 2016, 6, 321.
[http://dx.doi.org/10.3389/fphar.2015.00321] [PMID: 26793112]
[13]
Messoussi, A.; Feneyrolles, C.; Bros, A.; Deroide, A.; Daydé-Cazals, B.; Chevé, G.; Van Hijfte, N.; Fauvel, B.; Bougrin, K.; Yasri, A. Recent progress in the design, study and development of c-Jun N-terminal kinase inhibitors as anticancer agents. Chem. Biol., 2014, 21(11), 1433-1443.
[http://dx.doi.org/10.1016/j.chembiol.2014.09.007] [PMID: 25442375]
[14]
Ferrao, P.T. Taking out the JNK: a window of opportunity to improve cancer therapy. Mol. Cell. Oncol., 2016, 3(3)e1128515
[http://dx.doi.org/10.1080/23723556.2015.1128515] [PMID: 27314087]
[15]
Liu, J.; Wang, T.; Creighton, C.J.; Wu, S.P.; Ray, M.; Janardhan, K.S.; Willson, C.J.; Cho, S.N.; Castro, P.D.; Ittmann, M.M.; Li, J.L.; Davis, R.J.; DeMayo, F.J. JNK1/2 represses Lkb1-deficiency-induced lung squamous cell carcinoma progression. Nat. Commun., 2019, 10(1), 2148.
[http://dx.doi.org/10.1038/s41467-019-09843-1] [PMID: 31089135]
[16]
LoGrasso, P.; Kamenecka, T. Inhibitors of c-jun-N-terminal kinase (JNK). Mini Rev. Med. Chem., 2008, 8(8), 755-766.
[http://dx.doi.org/10.2174/138955708784912120] [PMID: 18673131]
[17]
Yan, C.; Kaoud, T.; Lee, S.; Dalby, K.N.; Ren, P. Understanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1. J. Phys. Chem. B, 2011, 115(6), 1491-1502.
[http://dx.doi.org/10.1021/jp1073522] [PMID: 21261310]
[18]
Smyth, L.A.; Collins, I. Measuring and interpreting the selectivity of protein kinase inhibitors. J. Chem. Biol., 2009, 2(3), 131-151.
[http://dx.doi.org/10.1007/s12154-009-0023-9] [PMID: 19568781]
[19]
Koch, P.; Gehringer, M.; Laufer, S.A. Inhibitors of c-Jun N-terminal kinases: an update. J. Med. Chem., 2015, 58(1), 72-95.
[http://dx.doi.org/10.1021/jm501212r] [PMID: 25415535]
[20]
Graczyk, P.P. JNK inhibitors as anti-inflammatory and neuroprotective agents. Future Med. Chem., 2013, 5(5), 539-551.
[http://dx.doi.org/10.4155/fmc.13.34] [PMID: 23573972]
[21]
Palmer, S.S.; Altan, M.; Denis, D.; Tos, E.G.; Gotteland, J.P.; Osteen, K.G.; Bruner-Tran, K.L.; Nataraja, S.G. Bentamapimod (JNK Inhibitor AS602801) induces regression of endometriotic lesions in animal models. Reprod. Sci., 2016, 23(1), 11-23.
[http://dx.doi.org/10.1177/1933719115600553] [PMID: 26335175]
[22]
Yamamoto, M.; Suzuki, S.; Togashi, K.; Sanomachi, T.; Seino, S.; Kitanaka, C.; Okada, M. AS602801 sensitizes ovarian cancer stem cells to paclitaxel by down-regulating MDR1. Anticancer Res., 2019, 39(2), 609-617.
[http://dx.doi.org/10.21873/anticanres.13154] [PMID: 30711936]
[23]
Yamamoto, M.; Suzuki, S.; Togashi, K.; Sanomachi, T.; Seino, S.; Kitanaka, C.; Okada, M. AS602801, an anticancer stem cell candidate drug, reduces survivin expression and sensitizes A2780 ovarian cancer stem cells to carboplatin and paclitaxel. Anticancer Res., 2018, 38(12), 6699-6706.
[http://dx.doi.org/10.21873/anticanres.13038] [PMID: 30504379]
[24]
Krenitsky, V.P.; Nadolny, L.; Delgado, M.; Ayala, L.; Clareen, S.S.; Hilgraf, R.; Albers, R.; Hegde, S.; D’Sidocky, N.; Sapienza, J.; Wright, J.; McCarrick, M.; Bahmanyar, S.; Chamberlain, P.; Delker, S.L.; Muir, J.; Giegel, D.; Xu, L.; Celeridad, M.; Lachowitzer, J.; Bennett, B.; Moghaddam, M.; Khatsenko, O.; Katz, J.; Fan, R.; Bai, A.; Tang, Y.; Shirley, M.A.; Benish, B.; Bodine, T.; Blease, K.; Raymon, H.; Cathers, B.E.; Satoh, Y. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg. Med. Chem. Lett., 2012, 22(3), 1433-1438.
[http://dx.doi.org/10.1016/j.bmcl.2011.12.027] [PMID: 22244937]
[25]
van der Velden, J.L.J.; Ye, Y.; Nolin, J.D.; Hoffman, S.M.; Chapman, D.G.; Lahue, K.G.; Abdalla, S.; Chen, P.; Liu, Y.; Bennett, B.; Khalil, N.; Sutherland, D.; Smith, W.; Horan, G.; Assaf, M.; Horowitz, Z.; Chopra, R.; Stevens, R.M.; Palmisano, M.; Janssen-Heininger, Y.M.W.; Schafer, P.H. JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clin. Transl. Med., 2016, 5(1), 36.
[http://dx.doi.org/10.1186/s40169-016-0117-2] [PMID: 27590145]
[26]
Reich, N.; Tomcik, M.; Zerr, P.; Lang, V.; Dees, C.; Avouac, J.; Palumbo, K.; Horn, A.; Akhmetshina, A.; Beyer, C.; Xie, W.; Bennett, B.L.; Distler, O.; Schett, G.; Distler, J.H. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann. Rheum. Dis., 2012, 71(5), 737-745.
[http://dx.doi.org/10.1136/annrheumdis-2011-200412] [PMID: 22258492]
[27]
Deo, N.; El-Hoss, J.; Kolind, M.; Mikulec, K.; Peacock, L.; Little, D.G.; Schindeler, A. JNK inhibitor CC-930 reduces fibrosis in a murine model of Nf1-deficient fracture repair. J. Appl. Biomed., 2018, 16(4), 350-357.
[http://dx.doi.org/10.1016/j.jab.2018.01.006]
[28]
Zheng, S.; Long, L.; Li, Y.; Xu, Y.; Jiqin, Z.; Ji, W.; Min, W. A novel ASK inhibitor AGI-1067 inhibits TLR-4-mediated activation of ASK1 by preventing dissociation of thioredoxin from ASK1. Cardiovasc. Pharm. Open Access, 2015, 4(1), 132.
[http://dx.doi.org/10.4172/2329-6607.1000132] [PMID: 28435845]
[29]
Liu, Z.; Shi, S.; Zhu, H.; Chen, Y.; Zhang, Y.; Zheng, Z.; Wang, X. Novel ASK1 inhibitor AGI-1067 attenuates AGE-induced fibrotic response by suppressing the MKKs/p38 MAPK pathway in human coronary arterial smooth muscle cells. Int. Heart J., 2018, 59(6), 1416-1424.
[http://dx.doi.org/10.1536/ihj.17-625] [PMID: 30305582]
[30]
Liu, Z.; Zheng, S.; Wang, X.; Qiu, C.; Guo, Y. Novel ASK1 inhibitor AGI-1067 improves AGE-induced cardiac dysfunction by inhibiting MKKs/p38 MAPK and NF-B apoptotic signaling. FEBS Open Bio, 2018, 8(9), 1445-1456.
[http://dx.doi.org/10.1002/2211-5463.12499] [PMID: 30186746]
[31]
Vasilevskaya, I.A.; Selvakumaran, M.; Hierro, L.C.; Goldstein, S.R.; Winkler, J.D.; O’Dwyer, P.J. Inhibition of JNK sensitizes hypoxic colon cancer cells to DNA-damaging agents. Clin. Cancer Res., 2015, 21(18), 4143-4152.
[http://dx.doi.org/10.1158/1078-0432.ccr-15-0352] [PMID: 26023085]
[32]
Abdolazimi, Y.; Zhao, Z.; Lee, S.; Xu, H.; Allegretti, P.; Horton, T.M.; Yeh, B.; Moeller, H.P.; Nichols, R.J.; McCutcheon, D.; Shalizi, A.; Smith, M.; Armstrong, N.A.; Annes, J.P. CC-401 promotes β-cell replication via pleiotropic consequences of DYRK1A/B inhibition. Endocrinology, 2018, 159(9), 3143-3157.
[http://dx.doi.org/10.1210/en.2018-00083] [PMID: 29514186]
[33]
Bowers, S.; Truong, A.P.; Jeffrey Neitz, R.; Hom, R.K.; Sealy, J.M.; Probst, G.D.; Quincy, D.; Peterson, B.; Chan, W.; Galemmo, R.A. Jr.; Konradi, A.W.; Sham, H.L.; Tóth, G.; Pan, H.; Lin, M.; Yao, N.; Artis, D.R.; Zhang, H.; Chen, L.; Dryer, M.; Samant, B.; Zmolek, W.; Wong, K.; Lorentzen, C.; Goldbach, E.; Tonn, G.; Quinn, K.P.; Sauer, J.M.; Wright, S.; Powell, K.; Ruslim, L.; Ren, Z.; Bard, F.; Yednock, T.A.; Griswold-Prenner, I. Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration. Bioorg. Med. Chem. Lett., 2011, 21(18), 5521-5527.
[http://dx.doi.org/10.1016/j.bmcl.2011.06.100] [PMID: 21813278]
[34]
Haynes, N.E.; Scott, N.R.; Chen, L.C.; Janson, C.A.; Li, J.K.; Lukacs, C.M.; Railkar, A.; Tozzo, E.; Whittard, T.; Brown, N.F.; Cheung, A.W. Identification of an adamantyl azaquinolone JNK selective inhibitor. ACS Med. Chem. Lett., 2012, 3(9), 764-768.
[http://dx.doi.org/10.1021/ml300175c] [PMID: 24900545]
[35]
Gong, L.; Han, X.; Silva, T.; Tan, Y.C.; Goyal, B.; Tivitmahaisoon, P.; Trejo, A.; Palmer, W.; Hogg, H.; Jahagir, A.; Alam, M.; Wagner, P.; Stein, K.; Filonova, L.; Loe, B.; Makra, F.; Rotstein, D.; Rapatova, L.; Dunn, J.; Zuo, F.; Dal Porto, J.; Wong, B.; Jin, S.; Chang, A.; Tran, P.; Hsieh, G.; Niu, L.; Shao, A.; Reuter, D.; Hermann, J.; Kuglstatter, A.; Goldstein, D. Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties. Bioorg. Med. Chem. Lett., 2013, 23(12), 3565-3569.
[http://dx.doi.org/10.1016/j.bmcl.2013.04.029] [PMID: 23664880]
[36]
Palmer, W.S.; Alam, M.; Arzeno, H.B.; Chang, K.C.; Dunn, J.P.; Goldstein, D.M.; Gong, L.; Goyal, B.; Hermann, J.C.; Hogg, J.H.; Hsieh, G.; Jahangir, A.; Janson, C.; Jin, S.; Ursula Kammlott, R.; Kuglstatter, A.; Lukacs, C.; Michoud, C.; Niu, L.; Reuter, D.C.; Shao, A.; Silva, T.; Trejo-Martin, T.A.; Stein, K.; Tan, Y.C.; Tivitmahaisoon, P.; Tran, P.; Wagner, P.; Weller, P.; Wu, S.Y. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead. Bioorg. Med. Chem. Lett., 2013, 23(5), 1486-1492.
[http://dx.doi.org/10.1016/j.bmcl.2012.12.047] [PMID: 23352510]
[37]
Li, B.; Cociorva, O.M.; Nomanbhoy, T.; Weissig, H.; Li, Q.; Nakamura, K.; Liyanage, M.; Zhang, M.C.; Shih, A.Y.; Aban, A.; Hu, Y.; Cajica, J.; Pham, L.; Kozarich, J.W.; Shreder, K.R. Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors. Bioorg. Med. Chem. Lett., 2013, 23(18), 5217-5222.
[http://dx.doi.org/10.1016/j.bmcl.2013.06.087] [PMID: 23916259]
[38]
Park, H.; Iqbal, S.; Hernandez, P.; Mora, R.; Zheng, K.; Feng, Y.; LoGrasso, P. Structural basis and biological consequences for JNK2/3 isoform selective aminopyrazoles. Sci. Rep., 2015, 5, 8047.
[http://dx.doi.org/10.1038/srep08047] [PMID: 25623238]
[39]
Zheng, K.; Park, C.M.; Iqbal, S.; Hernandez, P.; Park, H.; LoGrasso, P.V.; Feng, Y. Pyridopyrimidinone derivatives as potent and selective c-Jun N-terminal kinase (JNK) inhibitors. ACS Med. Chem. Lett., 2015, 6(4), 413-418.
[http://dx.doi.org/10.1021/ml500474d] [PMID: 25893042]
[40]
Ansideri, F.; Macedo, J.T.; Eitel, M.; El-Gokha, A.; Zinad, D.S.; Scarpellini, C.; Kudolo, M.; Schollmeyer, D.; Boeckler, F.M.; Blaum, B.S.; Laufer, S.A.; Koch, P. Structural optimization of a pyridinylimidazole scaffold: shifting the selectivity from p38α mitogen-activated protein kinase to c-Jun N-terminal kinase 3. ACS Omega, 2018, 3(7), 7809-7831.
[http://dx.doi.org/10.1021/acsomega.8b00668] [PMID: 30087925]
[41]
Bennett, B.L.; Sasaki, D.T.; Murray, B.W.; O’Leary, E.C.; Sakata, S.T.; Xu, W.; Leisten, J.C.; Motiwala, A.; Pierce, S.; Satoh, Y.; Bhagwat, S.S.; Manning, A.M.; Anderson, D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA, 2001, 98(24), 13681-13686.
[http://dx.doi.org/10.1073/pnas.251194298] [PMID: 11717429]
[42]
Shen, H.; Wu, N.; Wang, Y.; Han, X.; Zheng, Q.; Cai, X.; Zhang, H.; Zhao, M. JNK inhibitor SP600125 attenuates paraquat-induced acute lung injury: an in vivo and in vitro study. 2017, 40(4), 1319-1330.
[http://dx.doi.org/10.1007/s10753-017-0575-8] [PMID: 28474156]
[43]
Wu, H.M.; Fang, L.; Shen, Q.Y.; Liu, R.Y. SP600125 promotes resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model. Mol. Immunol., 2015, 67(2 Pt B), 311-316.
[http://dx.doi.org/10.1016/j.molimm.2015.06.016] [PMID: 26139014]
[44]
Liu, Y.; Song, Y.; Zhu, X. MicroRNA-181a regulates apoptosis and autophagy process in Parkinson’s disease by inhibiting p38 mitogen-activated protein kinase (MAPK)/c-Jun N-terminal kinases (JNK) signaling pathways. Med. Sci. Monit., 2017, 23, 1597-1606.
[http://dx.doi.org/10.12659/MSM.900218] [PMID: 28365714]
[45]
Grassi, E.S.; Vezzoli, V.; Negri, I.; Lábadi, Á.; Fugazzola, L.; Vitale, G.; Persani, L. SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways. Oncotarget, 2015, 6(34), 36383-36399.
[http://dx.doi.org/10.18632/oncotarget.5799] [PMID: 26415230]
[46]
Schepetkin, I.A.; Kirpotina, L.N.; Khlebnikov, A.I.; Hanks, T.S.; Kochetkova, I.; Pascual, D.W.; Jutila, M.A.; Quinn, M.T. Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. Mol. Pharmacol., 2012, 81(6), 832-845.
[http://dx.doi.org/10.1124/mol.111.077446] [PMID: 22434859]
[47]
Kamenecka, T.; Habel, J.; Duckett, D.; Chen, W.; Ling, Y.Y.; Frackowiak, B.; Jiang, R.; Shin, Y.; Song, X.; LoGrasso, P. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38. J. Biol. Chem., 2009, 284(19), 12853-12861.
[http://dx.doi.org/10.1074/jbc.M809430200] [PMID: 19261605]
[48]
Gaillard, P.; Jeanclaude-Etter, I.; Ardissone, V.; Arkinstall, S.; Cambet, Y.; Camps, M.; Chabert, C.; Church, D.; Cirillo, R.; Gretener, D.; Halazy, S.; Nichols, A.; Szyndralewiez, C.; Vitte, P.A.; Gotteland, J.P. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J. Med. Chem., 2005, 48(14), 4596-4607.
[http://dx.doi.org/10.1021/jm0310986] [PMID: 15999997]
[49]
Swahn, B.M.; Huerta, F.; Kallin, E.; Malmström, J.; Weigelt, T.; Viklund, J.; Womack, P.; Xue, Y.; Ohberg, L. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg. Med. Chem. Lett., 2005, 15(22), 5095-5099.
[http://dx.doi.org/10.1016/j.bmcl.2005.06.083] [PMID: 16140012]
[50]
Jiang, R.; Frackowiak, B.; Shin, Y.; Song, X.; Chen, W.; Lin, L.; Cameron, M.D.; Duckett, D.R.; Kamenecka, T.M. Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors. Bioorg. Med. Chem. Lett., 2013, 23(9), 2683-2687.
[http://dx.doi.org/10.1016/j.bmcl.2013.02.082] [PMID: 23518277]
[51]
He, Y.; Kamenecka, T.M.; Shin, Y.; Song, X.; Jiang, R.; Noel, R.; Duckett, D.; Chen, W.; Ling, Y.Y.; Cameron, M.D.; Lin, L.; Khan, S.; Koenig, M.; LoGrasso, P.V. Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(6), 1719-1723.
[http://dx.doi.org/10.1016/j.bmcl.2011.01.079] [PMID: 21316221]
[52]
Bowers, S.; Truong, A.P.; Neitz, R.J.; Neitzel, M.; Probst, G.D.; Hom, R.K.; Peterson, B.; Galemmo, R.A. Jr.; Konradi, A.W.; Sham, H.L.; Tóth, G.; Pan, H.; Yao, N.; Artis, D.R.; Brigham, E.F.; Quinn, K.P.; Sauer, J.M.; Powell, K.; Ruslim, L.; Ren, Z.; Bard, F.; Yednock, T.A.; Griswold-Prenner, I. Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor. Bioorg. Med. Chem. Lett., 2011, 21(6), 1838-1843.
[http://dx.doi.org/10.1016/j.bmcl.2011.01.046] [PMID: 21316234]
[53]
Schepetkin, I.A.; Khlebnikov, A.I.; Potapov, A.S.; Kovrizhina, A.R.; Matveevskaya, V.V.; Belyanin, M.L.; Atochin, D.N.; Zanoza, S.O.; Gaidarzhy, N.M.; Lyakhov, S.A.; Kirpotina, L.N.; Quinn, M.T. Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors. Eur. J. Med. Chem., 2019, 161, 179-191.
[http://dx.doi.org/10.1016/j.ejmech.2018.10.023] [PMID: 30347329]
[54]
Asano, Y.; Kitamura, S.; Ohra, T.; Aso, K.; Igata, H.; Tamura, T.; Kawamoto, T.; Tanaka, T.; Sogabe, S.; Matsumoto, S.; Yamaguchi, M.; Kimura, H.; Itoh, F. Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1). Bioorg. Med. Chem., 2008, 16(8), 4715-4732.
[http://dx.doi.org/10.1016/j.bmc.2008.02.027] [PMID: 18313304]
[55]
Asano, Y.; Kitamura, S.; Ohra, T.; Itoh, F.; Kajino, M.; Tamura, T.; Kaneko, M.; Ikeda, S.; Igata, H.; Kawamoto, T.; Sogabe, S.; Matsumoto, S.; Tanaka, T.; Yamaguchi, M.; Kimura, H.; Fukumoto, S. Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (2). Bioorg. Med. Chem., 2008, 16(8), 4699-4714.
[http://dx.doi.org/10.1016/j.bmc.2008.02.028] [PMID: 18313930]
[56]
Alam, M.; Beevers, R.E.; Ceska, T.; Davenport, R.J.; Dickson, K.M.; Fortunato, M.; Gowers, L.; Haughan, A.F.; James, L.A.; Jones, M.W.; Kinsella, N.; Lowe, C.; Meissner, J.W.; Nicolas, A.L.; Perry, B.G.; Phillips, D.J.; Pitt, W.R.; Platt, A.; Ratcliffe, A.J.; Sharpe, A.; Tait, L.J. Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(12), 3463-3467.
[http://dx.doi.org/10.1016/j.bmcl.2007.03.078] [PMID: 17459703]
[57]
Gong, L.; Tan, Y.C.; Boice, G.; Abbot, S.; McCaleb, K.; Iyer, P.; Zuo, F.; Dal Porto, J.; Wong, B.; Jin, S.; Chang, A.; Tran, P.; Hsieh, G.; Niu, L.; Shao, A.; Reuter, D.; Lukacs, C.M.; Ursula Kammlott, R.; Kuglstatter, A.; Goldstein, D. Discovery of a novel series of 4-quinolone JNK inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(24), 7381-7387.
[http://dx.doi.org/10.1016/j.bmcl.2012.10.066] [PMID: 23142618]
[58]
Rückle, T.; Biamonte, M.; Grippi-Vallotton, T.; Arkinstall, S.; Cambet, Y.; Camps, M.; Chabert, C.; Church, D.J.; Halazy, S.; Jiang, X.; Martinou, I.; Nichols, A.; Sauer, W.; Gotteland, J.P. Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl) thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase. J. Med. Chem., 2004, 47(27), 6921-6934.
[http://dx.doi.org/10.1021/jm031112e] [PMID: 15615541]
[59]
Cerbone, A.; Toaldo, C.; Pizzimenti, S.; Pettazzoni, P.; Dianzani, C.; Minelli, R.; Ciamporcero, E.; Roma, G.; Dianzani, M.U.; Canaparo, R.; Ferretti, C.; Barrera, G. AS601245, an anti-inflammatory JNK inhibitor, and clofibrate have a synergistic effect in inducing cell responses and in affecting the gene expression profile in CaCo-2 colon cancer cells. PPAR Res., 2012, 2012269751
[http://dx.doi.org/10.1155/2012/269751] [PMID: 22619672]
[60]
Carboni, S.; Hiver, A.; Szyndralewiez, C.; Gaillard, P.; Gotteland, J.P.; Vitte, P.A. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J. Pharmacol. Exp. Ther., 2004, 310(1), 25-32.
[http://dx.doi.org/10.1124/jpet.103.064246] [PMID: 14988419]
[61]
Angell, R.M.; Atkinson, F.L.; Brown, M.J.; Chuang, T.T.; Christopher, J.A.; Cichy-Knight, M.; Dunn, A.K.; Hightower, K.E.; Malkakorpi, S.; Musgrave, J.R.; Neu, M.; Rowland, P.; Shea, R.L.; Smith, J.L.; Somers, D.O.; Thomas, S.A.; Thompson, G.; Wang, R.N. -(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg. Med. Chem. Lett., 2007, 17(5), 1296-1301.
[http://dx.doi.org/10.1016/j.bmcl.2006.12.003] [PMID: 17194588]
[62]
Jiang, R.; Duckett, D.; Chen, W.; Habel, J.; Ling, Y.Y.; LoGrasso, P.; Kamenecka, T.M. 3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(22), 6378-6382.
[http://dx.doi.org/10.1016/j.bmcl.2007.08.054] [PMID: 17911023]
[63]
Song, X.; Chen, W.; Lin, L.; Ruiz, C.H.; Cameron, M.D.; Duckett, D.R.; Kamenecka, T.M. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(23), 7072-7075.
[http://dx.doi.org/10.1016/j.bmcl.2011.09.090] [PMID: 22004719]
[64]
Stocks, M.J.; Barber, S.; Ford, R.; Leroux, F.; St-Gallay, S.; Teague, S.; Xue, Y. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity. Bioorg. Med. Chem. Lett., 2005, 15(14), 3459-3462.
[http://dx.doi.org/10.1016/j.bmcl.2005.05.008] [PMID: 15950471]
[65]
Kim, M.H.; Lee, J.; Jung, K.; Kim, M.; Park, Y.J.; Ahn, H.; Kwon, Y.H.; Hah, J.M. Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects. Bioorg. Med. Chem., 2013, 21(8), 2271-2285.
[http://dx.doi.org/10.1016/j.bmc.2013.02.021] [PMID: 23498914]
[66]
Neitz, R.J.; Konradi, A.W.; Sham, H.L.; Zmolek, W.; Wong, K.; Qin, A.; Lorentzen, C.; Nakamura, D.; Quinn, K.P.; Sauer, J.M.; Powell, K.; Ruslim, L.; Chereau, D.; Ren, Z.; Anderson, J.; Bard, F.; Yednock, T.A.; Griswold-Prenner, I. Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement. Bioorg. Med. Chem. Lett., 2011, 21(12), 3726-3729.
[http://dx.doi.org/10.1016/j.bmcl.2011.04.074] [PMID: 21570836]
[67]
Liu, M.; Xin, Z.; Clampit, J.E.; Wang, S.; Gum, R.J.; Haasch, D.L.; Trevillyan, J.M.; Abad-Zapatero, C.; Fry, E.H.; Sham, H.L.; Liu, G. Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(10), 2590-2594.
[http://dx.doi.org/10.1016/j.bmcl.2006.02.046] [PMID: 16527482]
[68]
Kaneko, M.; Saito, Y.; Saito, H.; Matsumoto, T.; Matsuda, Y.; Vaught, J.L.; Dionne, C.A.; Angeles, T.S.; Glicksman, M.A.; Neff, N.T.; Rotella, D.P.; Kauer, J.C.; Mallamo, J.P.; Hudkins, R.L.; Murakata, C. Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. J. Med. Chem., 1997, 40(12), 1863-1869.
[http://dx.doi.org/10.1021/jm970031d] [PMID: 9191963]
[69]
Saporito, M.S.; Hudkins, R.L.; Maroney, A.C. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog. Med. Chem., 2002, 40, 23-62.
[http://dx.doi.org/10.1016/S0079-6468(08)70081-X] [PMID: 12516522]
[70]
Shoulson, I.; Schwid, S.; Hyson, C.; Oakes, D.; Gorbold, E.; Rudolph, A.; Shinaman, A.; Kamp, C.; Kieburtz, K.; Lang, A.; Fahn, S.; Gauger, L.; Goetz, C.; Marek, K.; Seibyl, J. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology, 2007, 69(15), 1480-1490.
[http://dx.doi.org/10.1212/01.wnl.0000277648.63931.c0] [PMID: 17881719]
[71]
Goettert, M.; Schattel, V.; Koch, P.; Merfort, I.; Laufer, S. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids. ChemBioChem, 2010, 11(18), 2579-2588.
[http://dx.doi.org/10.1002/cbic.201000487] [PMID: 21108268]
[72]
He, Y.; Duckett, D.; Chen, W.; Ling, Y.Y.; Cameron, M.D.; Lin, L.; Ruiz, C.H.; Lograsso, P.V.; Kamenecka, T.M.; Koenig, M. Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors. Bioorg. Med. Chem. Lett., 2014, 24(1), 161-164.
[http://dx.doi.org/10.1016/j.bmcl.2013.11.052] [PMID: 24332487]
[73]
Hom, R.K.; Bowers, S.; Sealy, J.M.; Truong, A.P.; Probst, G.D.; Neitzel, M.L.; Neitz, R.J.; Fang, L.; Brogley, L.; Wu, J.; Konradi, A.W.; Sham, H.L.; Tóth, G.; Pan, H.; Yao, N.; Artis, D.R.; Quinn, K.; Sauer, J.M.; Powell, K.; Ren, Z.; Bard, F.; Yednock, T.A.; Griswold-Prenner, I. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg. Med. Chem. Lett., 2010, 20(24), 7303-7307.
[http://dx.doi.org/10.1016/j.bmcl.2010.10.066] [PMID: 21071223]
[74]
Humphries, P.S.; Lafontaine, J.A.; Agree, C.S.; Alexander, D.; Chen, P.; Do, Q.Q.; Li, L.Y.; Lunney, E.A.; Rajapakse, R.J.; Siegel, K.; Timofeevski, S.L.; Wang, T.; Wilhite, D.M. Synthesis and SAR of 4-substituted-2-aminopyri-midines as novel c-Jun N-terminal kinase (JNK) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(8), 2099-2102.
[http://dx.doi.org/10.1016/j.bmcl.2009.03.023] [PMID: 19327989]
[75]
Shin, Y.; Chen, W.; Habel, J.; Duckett, D.; Ling, Y.Y.; Koenig, M.; He, Y.; Vojkovsky, T.; LoGrasso, P.; Kamenecka, T.M. Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(12), 3344-3347.
[http://dx.doi.org/10.1016/j.bmcl.2009.03.086] [PMID: 19433357]
[76]
Swahn, B.M.; Xue, Y.; Arzel, E.; Kallin, E.; Magnus, A.; Plobeck, N.; Viklund, J. Design and synthesis of 2′-anilino-4,4′-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg. Med. Chem. Lett., 2006, 16(5), 1397-1401.
[http://dx.doi.org/10.1016/j.bmcl.2005.11.039] [PMID: 16337120]
[77]
Szczepankiewicz, B.G.; Kosogof, C.; Nelson, L.T.J.; Liu, G.; Liu, B.; Zhao, H.; Serby, M.D.; Xin, Z.; Liu, M.; Gum, R.J.; Haasch, D.L.; Wang, S.; Clampit, J.E.; Johnson, E.F.; Lubben, T.H.; Stashko, M.A.; Olejniczak, E.T.; Sun, C.; Dorwin, S.A.; Haskins, K.; Abad-Zapatero, C.; Fry, E.H.; Hutchins, C.W.; Sham, H.L.; Rondinone, C.M.; Trevillyan, J.M. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J. Med. Chem., 2006, 49(12), 3563-3580.
[http://dx.doi.org/10.1021/jm060199b] [PMID: 16759099]
[78]
Zhao, H.; Serby, M.D.; Xin, Z.; Szczepankiewicz, B.G.; Liu, M.; Kosogof, C.; Liu, B.; Nelson, L.T.; Johnson, E.F.; Wang, S.; Pederson, T.; Gum, R.J.; Clampit, J.E.; Haasch, D.L.; Abad-Zapatero, C.; Fry, E.H.; Rondinone, C.; Trevillyan, J.M.; Sham, H.L.; Liu, G. Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. J. Med. Chem., 2006, 49(15), 4455-4458.
[http://dx.doi.org/10.1021/jm060465l] [PMID: 16854050]
[79]
Doma, A.; Kulkarni, R.; Palakodety, R.; Sastry, G.N.; Sridhara, J.; Garlapati, A. Pyrazole derivatives as potent inhibitors of c-Jun N-terminal kinase: synthesis and SAR studies. Bioorg. Med. Chem., 2014, 22(21), 6209-6219.
[http://dx.doi.org/10.1016/j.bmc.2014.08.028] [PMID: 25261929]
[80]
Noël, R.; Shin, Y.; Song, X.; He, Y.; Koenig, M.; Chen, W.; Ling, Y.Y.; Lin, L.; Ruiz, C.H.; LoGrasso, P.; Cameron, M.D.; Duckett, D.R.; Kamenecka, T.M. Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(9), 2732-2735.
[http://dx.doi.org/10.1016/j.bmcl.2010.11.104] [PMID: 21185177]
[81]
Noel, R.; Song, X.; Shin, Y.; Banerjee, S.; Kojetin, D.; Lin, L.; Ruiz, C.H.; Cameron, M.D.; Burris, T.P.; Kamenecka, T.M. Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists. Bioorg. Med. Chem. Lett., 2012, 22(11), 3739-3742.
[http://dx.doi.org/10.1016/j.bmcl.2012.04.023] [PMID: 22560469]
[82]
Liu, M.; Wang, S.; Clampit, J.E.; Gum, R.J.; Haasch, D.L.; Rondinone, C.M.; Trevillyan, J.M.; Abad-Zapatero, C.; Fry, E.H.; Sham, H.L.; Liu, G. Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: synthesis and SAR studies. Bioorg. Med. Chem. Lett., 2007, 17(3), 668-672.
[http://dx.doi.org/10.1016/j.bmcl.2006.10.093] [PMID: 17107797]
[83]
Liu, G.; Zhao, H.; Liu, B.; Xin, Z.; Liu, M.; Kosogof, C.; Szczepankiewicz, B.G.; Wang, S.; Clampit, J.E.; Gum, R.J.; Haasch, D.L.; Trevillyan, J.M.; Sham, H.L. Aminopyridine carboxamides as c-Jun N-terminal kinase inhibitors: targeting the gatekeeper residue and beyond. Bioorg. Med. Chem. Lett., 2006, 16(22), 5723-5730.
[http://dx.doi.org/10.1016/j.bmcl.2006.08.097] [PMID: 16971120]
[84]
Wityak, J.; McGee, K.F.; Conlon, M.P.; Song, R.H.; Duffy, B.C.; Clayton, B.; Lynch, M.; Wang, G.; Freeman, E.; Haber, J.; Kitchen, D.B.; Manning, D.D.; Ismail, J.; Khmelnitsky, Y.; Michels, P.; Webster, J.; Irigoyen, M.; Luche, M.; Hultman, M.; Bai, M.; Kuok, I.D.; Newell, R.; Lamers, M.; Leonard, P.; Yates, D.; Matthews, K.; Ongeri, L.; Clifton, S.; Mead, T.; Deupree, S.; Wheelan, P.; Lyons, K.; Wilson, C.; Kiselyov, A.; Toledo-Sherman, L.; Beconi, M.; Muñoz-Sanjuan, I.; Bard, J.; Dominguez, C. Lead optimization toward proof-of-concept tools for Huntington’s disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors. J. Med. Chem., 2015, 58(7), 2967-2987.
[http://dx.doi.org/10.1021/jm5013598] [PMID: 25760409]
[85]
Foulkes, D.M.; Byrne, D.P.; Yeung, W.; Shrestha, S.; Bailey, F.P.; Ferries, S.; Eyers, C.E.; Keeshan, K.; Wells, C.; Drewry, D.H.; Zuercher, W.J.; Kannan, N.; Eyers, P.A. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. Sci. Signal., 2018, 11(549)eaat7951
[http://dx.doi.org/10.1126/scisignal.aat7951] [PMID: 30254057]
[86]
Lu, X.; Yu, L.; Zhang, Z.; Ren, X.; Smaill, J.B.; Ding, K. Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: current developments in medicinal chemistry. Med. Res. Rev., 2018, 38(5), 1550-1581.
[http://dx.doi.org/10.1002/med.21488] [PMID: 29377179]
[87]
Smith, C.I.E. From identification of the BTK kinase to effective management of leukemia. Oncogene, 2017, 36(15), 2045-2053.
[http://dx.doi.org/10.1038/onc.2016.343] [PMID: 27669440]
[88]
Liang, C.; Tian, D.; Ren, X.; Ding, S.; Jia, M.; Xin, M.; Thareja, S. The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. Eur. J. Med. Chem., 2018, 151, 315-326.
[http://dx.doi.org/10.1016/j.ejmech.2018.03.062] [PMID: 29631132]
[89]
Zhang, T.; Inesta-Vaquera, F.; Niepel, M.; Zhang, J.; Ficarro, S.B.; Machleidt, T.; Xie, T.; Marto, J.A.; Kim, N.; Sim, T.; Laughlin, J.D.; Park, H.; LoGrasso, P.V.; Patricelli, M.; Nomanbhoy, T.K.; Sorger, P.K.; Alessi, D.R.; Gray, N.S. Discovery of potent and selective covalent inhibitors of JNK. Chem. Biol., 2012, 19(1), 140-154.
[http://dx.doi.org/10.1016/j.chembiol.2011.11.010] [PMID: 22284361]
[90]
Muth, F.; El-Gokha, A.; Ansideri, F.; Eitel, M.; Döring, E.; Sievers-Engler, A.; Lange, A.; Boeckler, F.M.; Lämmerhofer, M.; Koch, P.; Laufer, S.A. Tri- and tetrasubstituted pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3. J. Med. Chem., 2017, 60(2), 594-607.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01180] [PMID: 27977190]
[91]
Stebbins, J.L.; De, S.K.; Pavlickova, P.; Chen, V.; Machleidt, T.; Chen, L.H.; Kuntzen, C.; Kitada, S.; Karin, M.; Pellecchia, M. Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor. J. Med. Chem., 2011, 54(18), 6206-6214.
[http://dx.doi.org/10.1021/jm200479c] [PMID: 21815634]
[92]
Borsello, T.; Clarke, P.G.; Hirt, L.; Vercelli, A.; Repici, M.; Schorderet, D.F.; Bogousslavsky, J.; Bonny, C. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med., 2003, 9(9), 1180-1186.
[http://dx.doi.org/10.1038/nm911] [PMID: 12937412]
[93]
Ngoei, K.R.; Catimel, B.; Milech, N.; Watt, P.M.; Bogoyevitch, M.A. A novel retro-inverso peptide is a preferential JNK substrate-competitive inhibitor. Int. J. Biochem. Cell Biol., 2013, 45(8), 1939-1950.
[http://dx.doi.org/10.1016/j.biocel.2013.06.006] [PMID: 23792175]
[94]
Kaoud, T.S.; Mitra, S.; Lee, S.; Taliaferro, J.; Cantrell, M.; Linse, K.D.; Van Den Berg, C.L.; Dalby, K.N. Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. ACS Chem. Biol., 2011, 6(6), 658-666.
[http://dx.doi.org/10.1021/cb200017n] [PMID: 21438496]
[95]
Ngoei, K.R.; Catimel, B.; Church, N.; Lio, D.S.; Dogovski, C.; Perugini, M.A.; Watt, P.M.; Cheng, H.C.; Ng, D.C.; Bogoyevitch, M.A. Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide. Biochem. J., 2011, 434(3), 399-413.
[http://dx.doi.org/10.1042/BJ20101244] [PMID: 21162712]
[96]
Stebbins, J.L.; De, S.K.; Machleidt, T.; Becattini, B.; Vazquez, J.; Kuntzen, C.; Chen, L.H.; Cellitti, J.F.; Riel-Mehan, M.; Emdadi, A.; Solinas, G.; Karin, M.; Pellecchia, M. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl. Acad. Sci. USA, 2008, 105(43), 16809-16813.
[http://dx.doi.org/10.1073/pnas.0805677105] [PMID: 18922779]
[97]
De, S.K.; Stebbins, J.L.; Chen, L.H.; Riel-Mehan, M.; Machleidt, T.; Dahl, R.; Yuan, H.; Emdadi, A.; Barile, E.; Chen, V.; Murphy, R.; Pellecchia, M. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J. Med. Chem., 2009, 52(7), 1943-1952.
[http://dx.doi.org/10.1021/jm801503n] [PMID: 19271755]
[98]
Busquets, O.; Ettcheto, M.; Verdaguer, E.; Castro-Torres, R.D.; Auladell, C.; Beas-Zarate, C.; Folch, J.; Camins, A. JNK1 inhibition by licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid. Neuropharmacology, 2018, 131, 440-452.
[http://dx.doi.org/10.1016/j.neuropharm.2017.10.030] [PMID: 29111385]
[99]
Yao, K.; Cho, Y.Y.; Bode, A.M.; Vummenthala, A.; Park, J.G.; Liu, K.; Pang, Y.P.; Dong, Z. A selective small-molecule inhibitor of c-Jun N-terminal kinase 1. FEBS Lett., 2009, 583(13), 2208-2212.
[http://dx.doi.org/10.1016/j.febslet.2009.06.017] [PMID: 19527717]
[100]
Hill, Z.B.; Perera, B.G.; Maly, D.J. A chemical genetic method for generating bivalent inhibitors of protein kinases. J. Am. Chem. Soc., 2009, 131(19), 6686-6688.
[http://dx.doi.org/10.1021/ja900871y] [PMID: 19391594]
[101]
Enkvist, E.; Lavogina, D.; Raidaru, G.; Vaasa, A.; Viil, I.; Lust, M.; Viht, K.; Uri, A. Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. J. Med. Chem., 2006, 49(24), 7150-7159.
[http://dx.doi.org/10.1021/jm0605942] [PMID: 17125267]
[102]
Lavogina, D.; Enkvist, E.; Uri, A. Bisubstrate inhibitors of protein kinases: from principle to practical applications. ChemMedChem, 2010, 5(1), 23-34.
[http://dx.doi.org/10.1002/cmdc.200900252] [PMID: 19774589]
[103]
Lee, J.H.; Kumar, S.; Lawrence, D.S. Stepwise combinatorial evolution of Akt bisubstrate inhibitors. ChemBioChem, 2008, 9(4), 507-509.
[http://dx.doi.org/10.1002/cbic.200700583] [PMID: 18224646]
[104]
Pflug, A.; Rogozina, J.; Lavogina, D.; Enkvist, E.; Uri, A.; Engh, R.A.; Bossemeyer, D. Diversity of bisubstrate binding modes of adenosine analogue-oligoarginine conjugates in protein kinase a and implications for protein substrate interactions. J. Mol. Biol., 2010, 403(1), 66-77.
[http://dx.doi.org/10.1016/j.jmb.2010.08.028] [PMID: 20732331]
[105]
Fischer, P.M. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr. Protein Pept. Sci., 2003, 4(5), 339-356.
[http://dx.doi.org/10.2174/1389203033487054] [PMID: 14529528]
[106]
Feng, Y.; Chambers, J.W.; Iqbal, S.; Koenig, M.; Park, H.; Cherry, L.; Hernandez, P.; Figuera-Losada, M.; LoGrasso, P.V. A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases. ACS Chem. Biol., 2013, 8(8), 1747-1754.
[http://dx.doi.org/10.1021/cb3006165] [PMID: 23751758]
[107]
Chen, T.; Kablaoui, N.; Little, J.; Timofeevski, S.; Tschantz, W.R.; Chen, P.; Feng, J.; Charlton, M.; Stanton, R.; Bauer, P. Identification of small-molecule inhibitors of the JIP-JNK interaction. Biochem. J., 2009, 420(2), 283-294.
[http://dx.doi.org/10.1042/BJ20081899] [PMID: 19243309]
[108]
De, S.K.; Barile, E.; Chen, V.; Stebbins, J.L.; Cellitti, J.F.; Machleidt, T.; Carlson, C.B.; Yang, L.; Dahl, R.; Pellecchia, M. Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase. Bioorg. Med. Chem., 2011, 19(8), 2582-2588.
[http://dx.doi.org/10.1016/j.bmc.2011.03.017] [PMID: 21458276]
[109]
Dou, X.; Huang, H.; Li, Y.; Jiang, L.; Wang, Y.; Jin, H.; Jiao, N.; Zhang, L.; Zhang, L.; Liu, Z. Multistage screening reveals 3-substituted indolin-2-one derivatives as novel and isoform-selective c-Jun N-terminal kinase 3 (JNK3) inhibitors: implications to drug discovery for potential treatment of neurodegenerative diseases. J. Med. Chem., 2019, 62(14), 6645-6664.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00537] [PMID: 31268308]
[110]
Laurini, E.; Posocco, P.; Fermeglia, M.; Gibbons, D.L.; Quintás-Cardama, A.; Pricl, S. Through the open door: preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments. Mol. Oncol., 2013, 7(5), 968-975.
[http://dx.doi.org/10.1016/j.molonc.2013.06.001] [PMID: 23816609]
[111]
Goldblatt, M.; Huggins, J.T.; Doelken, P.; Gurung, P.; Sahn, S.A. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am. J. Med. Sci., 2009, 338(5), 414-417.
[http://dx.doi.org/10.1097/MAJ.0b013e3181ae9227] [PMID: 19838099]

Rights & Permissions Print Cite
Article Metrics
78
5
1
© 2024 Bentham Science Publishers | Privacy Policy